Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Abstract

EGFR mutations were a good predictor of clinical benefit of gefitinib in this setting.